LGND Ligand Pharmaceuticals Forecast, Technical & Fundamental Analysis

LGND's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for LGND turned positive on September 03, 2026. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in 258 of 340 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

LGND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 58 cases where LGND's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

The Momentum Indicator moved below the 0 level on September 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LGND as a result. In 67 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

LGND moved below its 50-day moving average on August 18, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LGND crossed bearishly below the 50-day moving average on August 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

The Aroon Indicator for LGND entered a downward trend on September 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.862) is normal, around the industry mean (19.994). P/E Ratio (29.306) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (21.008) is also within normal values, averaging (427.627).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.